Core Viewpoint - Watson Bio's subsidiary, Yuxi Zerun Biotechnology Co., Ltd., has successfully entered the bid for the "2025 National Immunization Program Vaccine Centralized Procurement Project" for the bivalent human papillomavirus (HPV) vaccine, which will enhance the vaccination rate in China and support the goal of cervical cancer elimination [1][2] Group 1 - Yuxi Zerun's bivalent HPV vaccine has been included in the procurement project with a unit price of RMB 27.5 [1] - The vaccine is primarily used to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer and related lesions [1] - The vaccine was officially launched in China in 2022 and received WHO prequalification in August 2024 [1] Group 2 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, and Yuxi Zerun will need to sign procurement contracts and manage production and supply [2] - The inclusion in the procurement project is expected to expand the sales scale of the bivalent HPV vaccine and enhance market coverage and brand influence [2] - There are two companies included in the procurement, and negotiations with provinces for market share will take place, which may not significantly impact the company's short-term operating performance [2]

Core Viewpoint - Watson Bio's subsidiary, Yuxi Zerun Biotechnology, has been selected for the 2025 National Immunization Program's centralized procurement project for the bivalent human papillomavirus (HPV) vaccine, with a unit price of RMB 27.5 [1] Group 1 - The bivalent HPV vaccine is primarily used for the prevention of cervical cancer and other diseases, and it has already been launched in the domestic market and received pre-certification from the World Health Organization [1] - The inclusion in the procurement project is expected to expand the sales scale of the company's bivalent HPV vaccine and improve market coverage [1] - However, the short-term impact on the company's performance is limited, and there is uncertainty regarding the final results and actual effects [1]

Core Viewpoint - Company WanTai BioPharma (603392.SH) has successfully entered the bidding for the 2025 National Immunization Program vaccine procurement project for the bivalent human papillomavirus (HPV) vaccine, with a unit price of RMB 27.5 [1][2] Group 1 - The bivalent HPV vaccine (E. coli) is designed to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer and various cervical intraepithelial neoplasia (CIN) [1] - The company has responded to the World Health Organization's initiative to eliminate cervical cancer globally, with global sales of the product reaching approximately 80 million doses as of the announcement date [1] - The inclusion of the product in the procurement project is expected to enhance the HPV vaccination rate in China, contributing to the country's goal of eliminating cervical cancer [1] Group 2 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, and if the company signs procurement contracts and organizes production and supply, it will help expand the sales scale of the included products [2] - This will improve the market share of the company's included products and promote the development of the domestic market, thereby enhancing the company's brand influence [2]

Core Viewpoint - The company, Wantai Biological Pharmacy Enterprise Co., Ltd. (万泰生物), announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has participated in the bidding for the 2025 National Immunization Program vaccine centralized procurement project for the bivalent human papillomavirus vaccine, successfully making it onto the procurement list [1] Group 1 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, indicating a significant government initiative in vaccine procurement [1] - If the company signs the procurement contract and organizes production and supply, it will help expand the sales scale of the listed products and increase market share [1] - This development is expected to promote the domestic market expansion of the company's listed products and enhance its brand influence [1]

Group 1 - The core viewpoint of the article highlights the inclusion of the HPV vaccine in China's national immunization program, indicating a significant step in public health policy [1] - The announcement of the centralized procurement project for the bivalent human papillomavirus vaccine has a budget of approximately 425 million yuan, with a total quantity of 15.4465 million doses [1] - The maximum price per dose is set at no more than 27.5 yuan, which reflects the government's effort to make the vaccine more accessible [1]